Bioengineered proteins are designed as the fundamental participants in all biological processes, represent as powerful therapeutic agents and include a broad range of products such as growth factors, hormones, vaccines, monoclonal antibodies, cytokines and few others. These special drugs are gaining attention across pharmaceutical industries due to their specificity, safety, bioreactivity and success rate in treating life-threatening diseases and injuries. In 2019, the market size of Bioengineered Protein Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Bioengineered Protein Drugs. This report studies the global market size of Bioengineered Protein Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia). This study presents the Bioengineered Protein Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019. In global market, the following companies are covered: Abbot Amgen Baxter Bayer Eli Lilly GlaxoSmithKline Fresenius Kabi Hoffman-la-Roche Johnson & Johnson Merck Market Segment by Product Type Recombinant protein drugs Peptide hormones Vaccines Therapeutic enzymes Monoclonal antibodies Cytokines Replacement proteins Peptide antibiotics Blood products Market Segment by Application Fractionation Bioreactors and microbial cell fermentation Genetic engineering Genetically modified organisms Pharming Bioengineered protein drugs produced by transgenic microorganisms, plants and animals Cell culture Others Key Regions split in this report: breakdown data for each region. United States China European Union Rest of World (Japan, Korea, India and Southeast Asia) The study objectives are: To analyze and research the Bioengineered Protein Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast. To present the key Bioengineered Protein Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players. To split the breakdown data by regions, type, companies and applications To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. To identify significant trends, drivers, influence factors in global and regions To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market In this study, the years considered to estimate the market size of Bioengineered Protein Drugs are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025
Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Major Manufacturers Covered in This Report 1.3 Market Segment by Type 1.3.1 Global Bioengineered Protein Drugs Market Size Growth Rate by Type (2019-2025) 1.3.2 Recombinant protein drugs 1.3.3 Peptide hormones 1.3.4 Vaccines 1.3.5 Therapeutic enzymes 1.3.6 Monoclonal anti
